Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 489

1.

Changes in immunosuppressive treatment of chronic graft-versus-host disease - comparison of 2 surveys within allogeneic hematopoietic stem cell transplant centers in Germany, Austria and Switzerland.

Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke JM, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H.

Biol Blood Marrow Transplant. 2019 Mar 12. pii: S1083-8791(19)30154-5. doi: 10.1016/j.bbmt.2019.03.003. [Epub ahead of print]

PMID:
30876928
2.

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.

Robin M, de Wreede LC, Wolschke C, Schetelig J, Eikema DJ, Van Lint MT, Knelange NS, Beelen D, Brecht A, Niederwieser D, Vitek A, Bethge W, Arnold R, Finke J, Volin L, Yakoub-Agha I, Nagler A, Poiré X, Einsele H, Chevallier P, Holler E, Ljungman P, Robinson S, Radujkovic A, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Feb 7. pii: haematol.2018.205211. doi: 10.3324/haematol.2018.205211. [Epub ahead of print]

3.

Blockade of a Laminin-411-Notch Axis with CRISPR/Cas9 or a Nanobioconjugate Inhibits Glioblastoma Growth through Tumor-Microenvironment Cross-talk.

Sun T, Patil R, Galstyan A, Klymyshyn D, Ding H, Chesnokova A, Cavenee WK, Furnari FB, Ljubimov VA, Shatalova ES, Wagner S, Li D, Mamelak AN, Bannykh SI, Patil CG, Rudnick JD, Hu J, Grodzinski ZB, Rekechenetskiy A, Falahatian V, Lyubimov AV, Chen YL, Leoh LS, Daniels-Wells TR, Penichet ML, Holler E, Ljubimov AV, Black KL, Ljubimova JY.

Cancer Res. 2019 Mar 15;79(6):1239-1251. doi: 10.1158/0008-5472.CAN-18-2725. Epub 2019 Jan 18.

PMID:
30659021
4.

A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymalic Acid Nanodrug Platform Across the Blood-Brain Barrier.

Israel LL, Braubach O, Galstyan A, Chiechi A, Shatalova ES, Grodzinski Z, Ding H, Black KL, Ljubimova JY, Holler E.

ACS Nano. 2019 Feb 26;13(2):1253-1271. doi: 10.1021/acsnano.8b06437. Epub 2019 Jan 16.

PMID:
30633492
5.

Non-invasive diagnosis of acute intestinal graft-versus-host disease by a new scoring system using ultrasound morphology, compound elastography, and contrast-enhanced ultrasound.

Weber D, Weber M, Hippe K, Ghimire S, Wolff D, Hahn J, Evert M, Herr W, Holler E, Jung EM.

Bone Marrow Transplant. 2018 Nov 6. doi: 10.1038/s41409-018-0381-4. [Epub ahead of print]

PMID:
30401964
6.

Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib.

Fante MA, Holler E, Schmidt B, Wolff D, Ehrl Y, Plentz A.

Bone Marrow Transplant. 2018 Oct 22. doi: 10.1038/s41409-018-0370-7. [Epub ahead of print] No abstract available.

PMID:
30349038
7.

Editorial: Cellular Therapies: Past, Present and Future.

Dressel R, Greinix HT, Holler E, Dickinson AM.

Front Immunol. 2018 Aug 30;9:1966. doi: 10.3389/fimmu.2018.01966. eCollection 2018. No abstract available.

8.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2018 Aug 23;3(16). pii: 124015. doi: 10.1172/jci.insight.124015. eCollection 2018 Aug 23. No abstract available.

9.

Detrimental effect of broad-spectrum antibiotics on intestinal microbiome diversity in patients after allogeneic stem cell transplantation: Lack of commensal sparing antibiotics.

Weber D, Hiergeist A, Weber M, Dettmer K, Wolff D, Hahn J, Herr W, Gessner A, Holler E.

Clin Infect Dis. 2018 Aug 17. doi: 10.1093/cid/ciy711. [Epub ahead of print]

PMID:
30124813
10.

[Tauopathies : From molecule to therapy].

Kovacs GG, Respondek G, van Eimeren T, Höller E, Levin J, Müller U, Schwarz S, Rösler TW, Schweyer K, Höglinger GU.

Nervenarzt. 2018 Oct;89(10):1083-1094. doi: 10.1007/s00115-018-0584-3. Review. German.

PMID:
30120488
11.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.

Holtan SG, DeFor TE, Panoskaltsis-Mortari A, Khera N, Levine JE, Flowers MED, Lee SJ, Inamoto Y, Chen GL, Mayer S, Arora M, Palmer J, Cutler CS, Arai S, Lazaryan A, Newell LF, Jagasia MH, Pusic I, Wood WA, Renteria AS, Yanik G, Hogan WJ, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera YA, Ferrara JLM, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar BR, Weisdorf DJ, MacMillan ML.

Blood Adv. 2018 Aug 14;2(15):1882-1888. doi: 10.1182/bloodadvances.2018017343.

12.

The influence of glucocorticoid receptor single nucleotide polymorphisms on outcome after haematopoietic stem cell transplantation.

Norden J, Pearce KF, Irving JAE, Collin MP, Wang XN, Wolff D, Kolb HJ, Socie G, Kuzmina Z, Greinix H, Holler E, Rocha V, Gluckman E, Hromadnikova I, Dickinson AM.

Int J Immunogenet. 2018 Jul 25. doi: 10.1111/iji.12380. [Epub ahead of print]

PMID:
30043490
13.

Targeting Inflammatory T Helper Cells via Retinoic Acid-Related Orphan Receptor Gamma t Is Ineffective to Prevent Allo-Response-Driven Colitis.

Buchele V, Abendroth B, Büttner-Herold M, Vogler T, Rothamer J, Ghimire S, Ullrich E, Holler E, Neurath MF, Hildner K.

Front Immunol. 2018 May 25;9:1138. doi: 10.3389/fimmu.2018.01138. eCollection 2018.

14.

EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment.

Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ; EBMT (European Society for Blood and Marrow Transplantation) Transplant Complications Working Party and the “EBMT−NIH (National Institutes of Health)−CIBMTR (Center for International Blood and Marrow Transplant Research) GvHD Task Force”.

Bone Marrow Transplant. 2018 Nov;53(11):1401-1415. doi: 10.1038/s41409-018-0204-7. Epub 2018 Jun 5.

PMID:
29872128
15.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2018 Aug;182(3):418-422. doi: 10.1111/bjh.15407. Epub 2018 May 29.

16.

Coarse particulate matter (PM2.5-10) in Los Angeles Basin air induces expression of inflammation and cancer biomarkers in rat brains.

Ljubimova JY, Braubach O, Patil R, Chiechi A, Tang J, Galstyan A, Shatalova ES, Kleinman MT, Black KL, Holler E.

Sci Rep. 2018 Apr 9;8(1):5708. doi: 10.1038/s41598-018-23885-3.

17.

Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma.

Heinzelmann F, Bethge W, Beelen DW, Stelljes M, Dreger P, Engelhard M, Finke J, Kröger N, Holler E, Bornhäuser M, Müller A, Haubitz I, Ottinger H.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1173-1183. doi: 10.1007/s00432-018-2633-5. Epub 2018 Apr 5.

PMID:
29623467
18.

Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity.

DeFilipp Z, Peled JU, Li S, Mahabamunuge J, Dagher Z, Slingerland AE, Del Rio C, Valles B, Kempner ME, Smith M, Brown J, Dey BR, El-Jawahri A, McAfee SL, Spitzer TR, Ballen KK, Sung AD, Dalton TE, Messina JA, Dettmer K, Liebisch G, Oefner P, Taur Y, Pamer EG, Holler E, Mansour MK, van den Brink MRM, Hohmann E, Jenq RR, Chen YB.

Blood Adv. 2018 Apr 10;2(7):745-753. doi: 10.1182/bloodadvances.2018017731.

19.

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.

Major-Monfried H, Renteria AS, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera YA, Hogan WJ, Wölfl M, Qayed M, Hexner EO, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell MJ, Chaudhry MS, Aziz M, Etra A, Yanik GA, Kröger N, Weber D, Chen YB, Nakamura R, Rösler W, Kitko CL, Harris AC, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara JLM, Levine JE.

Blood. 2018 Jun 21;131(25):2846-2855. doi: 10.1182/blood-2018-01-822957. Epub 2018 Mar 15.

PMID:
29545329
20.

The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future.

Andermann TM, Peled JU, Ho C, Reddy P, Riches M, Storb R, Teshima T, van den Brink MRM, Alousi A, Balderman S, Chiusolo P, Clark WB, Holler E, Howard A, Kean LS, Koh AY, McCarthy PL, McCarty JM, Mohty M, Nakamura R, Rezvani K, Segal BH, Shaw BE, Shpall EJ, Sung AD, Weber D, Whangbo J, Wingard JR, Wood WA, Perales MA, Jenq RR, Bhatt AS; Blood and Marrow Transplant Clinical Trials Network.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1322-1340. doi: 10.1016/j.bbmt.2018.02.009. Epub 2018 Feb 19. No abstract available.

PMID:
29471034
21.

BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.

Ullrich E, Abendroth B, Rothamer J, Huber C, Büttner-Herold M, Buchele V, Vogler T, Longerich T, Zundler S, Völkl S, Beilhack A, Rose-John S, Wirtz S, Weber GF, Ghimire S, Kreutz M, Holler E, Mackensen A, Neurath MF, Hildner K.

J Clin Invest. 2018 Mar 1;128(3):916-930. doi: 10.1172/JCI89242. Epub 2018 Jan 29.

22.

Biomarkers in chronic graft-versus-host disease: quo vadis?

Wolff D, Greinix H, Lee SJ, Gooley T, Paczesny S, Pavletic S, Hakim F, Malard F, Jagasia M, Lawitschka A, Hansen JA, Pulanic D, Holler E, Dickinson A, Weissinger E, Edinger M, Sarantopoulos S, Schultz KR.

Bone Marrow Transplant. 2018 Jul;53(7):832-837. doi: 10.1038/s41409-018-0092-x. Epub 2018 Jan 24.

23.

Indoxyl 3-sulfate inhibits maturation and activation of human monocyte-derived dendritic cells.

Ghimire S, Matos C, Caioni M, Weber D, Peter K, Holler E, Kreutz M, Renner K.

Immunobiology. 2018 Feb;223(2):239-245. doi: 10.1016/j.imbio.2017.10.014. Epub 2017 Oct 6.

PMID:
29100619
24.

Polymalic Acid Tritryptophan Copolymer Interacts with Lipid Membrane Resulting in Membrane Solubilization.

Ding H, Fox I, Patil R, Galstyan A, Black KL, Ljubimova JY, Holler E.

J Nanomater. 2017;2017. pii: 4238697. doi: 10.1155/2017/4238697. Epub 2017 May 21.

25.

The association between acute graft-versus-host disease and antimicrobial peptide expression in the gastrointestinal tract after allogeneic stem cell transplantation.

Weber D, Frauenschläger K, Ghimire S, Peter K, Panzer I, Hiergeist A, Weber M, Kutny D, Wolff D, Grube M, Huber E, Oefner P, Gessner A, Hehlgans T, Herr W, Holler E.

PLoS One. 2017 Sep 21;12(9):e0185265. doi: 10.1371/journal.pone.0185265. eCollection 2017.

26.

Acute Renal Graft-Versus-Host Disease in a Murine Model of Allogeneic Bone Marrow Transplantation.

Schmid PM, Bouazzaoui A, Schmid K, Birner C, Schach C, Maier LS, Holler E, Endemann DH.

Cell Transplant. 2017 Aug;26(8):1428-1440. doi: 10.1177/0963689717720295.

27.

Acute Ocular Graft-versus-Host Disease.

Braun R, Holler E.

N Engl J Med. 2017 Aug 17;377(7):676. doi: 10.1056/NEJMicm1701185. No abstract available.

28.

Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.

Klobuch S, Weber D, Holler B, Herr W, Holler E, Wolff D.

Oncol Res Treat. 2017;40(7-8):447-450. doi: 10.1159/000471768. Epub 2017 Jun 30.

29.

Endothelial damage is aggravated in acute GvHD and could predict its development.

Mir E, Palomo M, Rovira M, Pereira A, Escolar G, Penack O, Holler E, Carreras E, Diaz-Ricart M.

Bone Marrow Transplant. 2017 Sep;52(9):1317-1325. doi: 10.1038/bmt.2017.121. Epub 2017 Jun 26.

PMID:
28650450
30.

Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Stelljes M, Ehninger G, Schwerdtfeger R, Finke J, Kolb HJ, Ganser A, Schäfer-Eckart K, Zander AR, Bunjes D, Mielke S, Bethge WA, Milpied N, Kalhs P, Blau IW, Kröger N, Vitek A, Gramatzki M, Holler E, Schmid C, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jun 24;10(1):130. doi: 10.1186/s13045-017-0498-8.

31.

Complementary and Alternative Medicine: A Clinical Study in 1,016 Hematology/Oncology Patients.

Hierl M, Pfirstinger J, Andreesen R, Holler E, Mayer S, Wolff D, Vogelhuber M.

Oncology. 2017;93(3):157-163. doi: 10.1159/000464248. Epub 2017 Jun 23.

PMID:
28641281
32.

Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Ljubimova JY, Sun T, Mashouf L, Ljubimov AV, Israel LL, Ljubimov VA, Falahatian V, Holler E.

Adv Drug Deliv Rev. 2017 Apr;113:177-200. doi: 10.1016/j.addr.2017.06.002. Epub 2017 Jun 10. Review.

33.

Haploidentical stem cell transplantation with CD3+-/CD19+- depleted peripheral stem cells for patients with advanced stage sickle cell disease and no alternative donor: results of a pilot study.

Foell J, Pfirstinger B, Rehe K, Wolff D, Holler E, Corbacioglu S.

Bone Marrow Transplant. 2017 Jun;52(6):938-940. doi: 10.1038/bmt.2017.49. Epub 2017 Apr 24. No abstract available.

PMID:
28436975
34.

Pathophysiology of GvHD and Other HSCT-Related Major Complications.

Ghimire S, Weber D, Mavin E, Wang XN, Dickinson AM, Holler E.

Front Immunol. 2017 Mar 20;8:79. doi: 10.3389/fimmu.2017.00079. eCollection 2017. Review.

35.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2017 Jun;177(5):759-765. doi: 10.1111/bjh.14619. Epub 2017 Mar 28.

PMID:
28369779
36.

[Bilateral ciliary body oedema under treatment with ciclosporine].

Braun R, Holler E, Wolff D, Helbig H, Blecha C, Dietrich-Ntoukas T.

Ophthalmologe. 2018 Jan;115(1):55-58. doi: 10.1007/s00347-017-0475-1. German.

PMID:
28251308
37.

Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation.

Weber D, Jenq RR, Peled JU, Taur Y, Hiergeist A, Koestler J, Dettmer K, Weber M, Wolff D, Hahn J, Pamer EG, Herr W, Gessner A, Oefner PJ, van den Brink MRM, Holler E.

Biol Blood Marrow Transplant. 2017 May;23(5):845-852. doi: 10.1016/j.bbmt.2017.02.006. Epub 2017 Feb 14.

38.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.

Hartwell MJ, Özbek U, Holler E, Renteria AS, Major-Monfried H, Reddy P, Aziz M, Hogan WJ, Ayuk F, Efebera YA, Hexner EO, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen YB, Devine S, Harris AC, Jagasia M, Kitko CL, Litzow MR, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik GA, Levine JE, Ferrara JL.

JCI Insight. 2017 Feb 9;2(3):e89798. doi: 10.1172/jci.insight.89798.

39.

Fit for cure? Microbiota and GVHD.

Holler E, Weber D.

Blood. 2016 Oct 20;128(16):2004-2005. doi: 10.1182/blood-2016-08-732156. No abstract available.

40.

B-Cell-Based and Soluble Biomarkers in Body Liquids for Predicting Acute/Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Juric MK, Shevtsov M, Mozes P, Ogonek J, Crossland RE, Dickinson AM, Greinix HT, Holler E, Weissinger EM, Multhoff G.

Front Immunol. 2017 Jan 16;7:660. doi: 10.3389/fimmu.2016.00660. eCollection 2016. Review.

41.

Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation.

Ullrich E, Salzmann-Manrique E, Bakhtiar S, Bremm M, Gerstner S, Herrmann E, Bader P, Hoffmann P, Holler E, Edinger M, Wolff D.

Front Immunol. 2016 Dec 22;7:595. doi: 10.3389/fimmu.2016.00595. eCollection 2016.

42.

Reduction of aGVHD using chicken antibodies directed against intestinal pathogens in a murine model.

Bouazzaoui A, Huber E, Dan A, Al-Allaf FA, Pfirstinger J, Sprotte G, Köstler J, Hiergeist A, Gessner A, Herr W, Holler E.

Blood. 2017 Feb 23;129(8):1052-1055. doi: 10.1182/blood-2016-06-722538. Epub 2016 Dec 23. No abstract available.

43.

Antithymocyte Globulin Induces a Tolerogenic Phenotype in Human Dendritic Cells.

Roider T, Katzfuß M, Matos C, Singer K, Renner K, Oefner PJ, Dettmer-Wilde K, Herr W, Holler E, Kreutz M, Peter K.

Int J Mol Sci. 2016 Dec 11;17(12). pii: E2081.

44.

Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.

Bohmann EM, Fehn U, Holler B, Weber D, Holler E, Herr W, Hoffmann P, Edinger M, Wolff D.

Ann Hematol. 2017 Feb;96(2):299-310. doi: 10.1007/s00277-016-2881-x. Epub 2016 Dec 9.

PMID:
27942862
45.

Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation.

Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, Weissinger E.

Front Immunol. 2016 Nov 17;7:507. eCollection 2016. Review.

46.

Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments.

Juric MK, Ghimire S, Ogonek J, Weissinger EM, Holler E, van Rood JJ, Oudshoorn M, Dickinson A, Greinix HT.

Front Immunol. 2016 Nov 9;7:470. eCollection 2016. Review.

47.

Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia.

Pearce KF, Balavarca Y, Norden J, Jackson G, Holler E, Dressel R, Greinix H, Toubert A, Gluckman E, Hromadnikova I, Sedlacek P, Wolff D, Holtick U, Bickeböller H, Dickinson AM.

Int J Immunogenet. 2016 Dec;43(6):404-412. doi: 10.1111/iji.12295. Epub 2016 Nov 9.

PMID:
27870355
48.

Granulocytapheresis with modified fluid gelatin versus high-molecular-weight hydroxyethyl starch: a matched-pair analysis.

Dullinger K, Pamler I, Brosig A, Mohrez M, Hähnel V, Offner R, Dormann F, Becke C, Holler E, Ahrens N.

Transfusion. 2017 Feb;57(2):397-403. doi: 10.1111/trf.13898. Epub 2016 Nov 10.

PMID:
27859322
49.

Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.

Chou ST, Patil R, Galstyan A, Gangalum PR, Cavenee WK, Furnari FB, Ljubimov VA, Chesnokova A, Kramerov AA, Ding H, Falahatian V, Mashouf L, Fox I, Black KL, Holler E, Ljubimov AV, Ljubimova JY.

J Control Release. 2016 Dec 28;244(Pt A):14-23. doi: 10.1016/j.jconrel.2016.11.001. Epub 2016 Nov 5.

50.

The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation.

Weissinger EM, Human C, Metzger J, Hambach L, Wolf D, Greinix HT, Dickinson AM, Mullen W, Jonigk D, Kuzmina Z, Kreipe H, Schweier P, Böhm O, Türüchanow I, Ihlenburg-Schwarz D, Raad J, Durban A, Schiemann M, Könecke C, Diedrich H, Holler E, Beutel G, Krauter J, Ganser A, Stadler M.

Leukemia. 2017 Mar;31(3):654-662. doi: 10.1038/leu.2016.259. Epub 2016 Sep 28.

PMID:
27677743

Supplemental Content

Loading ...
Support Center